Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH

– First clinical data from the KOMET-001 study to be presented on December 5, 2020 – SAN DIEGO , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract reporting preliminary data from KOMET-001, an ongoing clinical trial of the Company’s oral, potent and selective menin inhibitor, KO-539, has been accepted for oral presentation at the 62 nd American Society of Hematology (ASH) Annual Meeting and Exposition. The following abstract will be posted on the ASH website at 9:00 a.m. ET on November 5, 2020 . Updated data will be presented at the meeting. Title: Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia Publication Number: 115 Session Name : 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel promising therapies for relapsed/refractory AML Session Date: Saturday, December 5, 2020 Session Time: 9:30 AM - 11:00 AM Presentation Time: 10:30 AM About KOMET-001 KOMET-001 (Kura Oncology Menin Inhibitor Trial) is a Phase 1/2A study to determine the safety, tolerability and recommended Phase 2 dose of KO-539 in patients with refractory or relapsed acute myeloid leukemia (AML). A planned expansion phase in specific genetic subgroups, including NPM1 mutant AML and KMT2A rearranged AML, is expected to further evaluate anti-leukemic activity and tolerability of KO-539. Additional information about the Phase 1/2A study of KO-539 can be found at kuraoncology.com/clinical-trials- komet . About KO-539 KO-539, an oral investigational drug candidate, is a novel compound targeting the menin-KMT2A (MLL) interaction for treatment of genetically defined AML patients with high unmet need. In preclinical models, KO-539 inhibits the KMT2A (MLL) protein complex and has downstream effects on HOXA9/MEIS1 expression. KO-539 has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed/refractory acute myeloid leukemia. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com . C ontacts Company: Pete De Spain Vice President, Investor Relations & Corporate Communications (858) 500-8803 [email protected] Investors: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] Media: Jason Spark Managing Director Canale Communications (619) 849-6005 [email protected] Source: Kura Oncology, Inc. Tools Print RSS Feeds Email Alerts Footer Links - Top About Us Our Commitment The Story Behind Our Name Leadership Board of Directors Grants & Funding Investigator Sponsored Studies Compliance Declaration Our Approach Precision Medicines Overcoming Resistance Novel Biomarkers Pipeline Menin Inhibition Farnesyl Transferase Inhibitors Posters and Presentations Scientific Manuscripts Access to Investigational Drugs Outside a Clinical Study Patients & Caregivers Acute Leukemias Head & Neck Cancer Our Medicine Footer Links - Investors New Investors Overview Press Releases Events & Presentations Corporate Governance Financial Information Analyst Coverage FAQs Contact Footer Links - Careers Careers Values Life at Kura Benefits Open Positions Footer Links - News & Media News & Media Press Releases News & Perspecitives Expert Perspectives Media Resources 01 Footer Links - Contact Contact Kura Oncology, Inc. 4930 Directors Place, Suite 500 San Diego, CA 92121 (858) 500-8800 Kura Oncology, Inc. 2 Seaport Lane, Suite 8A Boston, MA 02210 (617) 588-3755 © 2026 Kura Oncology, Inc. All Rights Reserved | Terms of Use | Privacy Policy | Cookie Policy | Consumer Health Data Scroll to top

The release as fetched from its publisher. kuraoncology.com ↗